Can a TKI Boost Anti-PD-L1 Activity in NSCLC?



Study reveals the advantages and pitfalls of adding a TKI to a monoclonal antibody after chemoradiation for non-small cell lung cancer.
Medscape Medical News



Source link : https://www.medscape.com/viewarticle/can-adding-tki-monoclonal-antibody-boost-anti-pd-l1-activity-2025a1000fmi?src=rss

Author :

Publish date : 2025-06-11 09:47:00

Copyright for syndicated content belongs to the linked Source.
Exit mobile version